SUPPLEMENTAL	ΜΔΤΕΡΙΔΙ	REI ONGING	$T\cap$
OUI I LLIVILIVIAL		DEEDINGIING	$I \cup I$

3

4

Distinct COVID-19 vaccine combinations result in divergent immune responses

5

- 6 Luca M. Zaeck^{1*}, Ngoc H. Tan^{2*}, Wim J.R. Rietdijk², Daryl Geers¹, Roos S.G. Sablerolles²,
- 7 Susanne Bogers¹, Laura L.A. van Dijk¹, Lennert Gommers¹, Leanne P.M. van Leeuwen¹, Sharona
- 8 Rugebregt¹, Abraham Goorhuis^{3,4}, Douwe F. Postma⁵, Leo G. Visser⁶, Virgil A.S.H. Dalm⁷, Melvin
- 9 Lafeber⁸, Neeltje A. Kootstra⁹, Anke L.W. Huckriede¹⁰, Bart L. Haagmans¹, Debbie van Baarle^{10,11},
- 10 Marion P.G. Koopmans¹, P. Hugo M. van der Kuy^{2#}, Corine H. GeurtsvanKessel^{1#\$}, Rory D. de
- 11 Vries^{1#}, SWITCH-ON Research Group[%]

12

- 13 Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- 14 ² Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands
- 15 ³ Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical
- 16 Centers, Amsterdam, the Netherlands
- 17 ⁴ Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands
- 18 ⁵ Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the
- 19 Netherlands
- 20 ⁶ Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- ⁷ Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of Immunology, Erasmus
- 22 Medical Center, Rotterdam, the Netherlands
- 23 8 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
- ⁹ Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Infection and Immunity
- 25 Institute, University of Amsterdam, Amsterdam, the Netherlands
- 26 ¹⁰ Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of
- 27 Groningen, Groningen, the Netherlands
- 28 ¹¹ Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the
- 29 Netherlands


30

- 31 * Contributed equally
- 32 # Contributed equally


33

34 % List of investigators from the SWITCH-ON research group is in Supplementary Table S1


- 36 \$ corresponding author: Corine H. GeurtsvanKessel, department of Viroscience, Erasmus Medical
- 37 Center, Rotterdam, 3015 GD, Netherlands, c.geurtsvankessel@erasmusmc.nl




Supplementary Figure S1. SWITCH-ON study design. a,b, Healthcare workers (HCW), who received either Ad26.COV2.S (red and yellow) or an mRNA-based (green and blue) priming vaccination regimen, followed by an additional boost with an mRNA-based vaccine, were vaccinated with either bivalent Omicron BA.1 (**a**, direct boost group) or BA.5 (**b**, postponed boost group). Blood samples were collected at baseline before bivalent vaccination (study visit 1, SV1), at 7 (study visit 2, SV2) and 28 days post-vaccination (study visit 3, SV3), and at approximately 3 months-post vaccination (study visit 4, SV4). The numerical value in brackets indicates the IQR of days deviating from the intended interval.




Supplementary Figure S2. Ancestral SARS-CoV-2 neutralizing antibodies and T-cell responses in subgroups based on the different combinations of prime and boost. a-d, Detection of T-cell responses measured by interferon-gamma (IFN-γ) release assay (IGRA) (a,b), and ancestral SARS-CoV-2 neutralizing antibodies (c,d) after Omicron BA.1 (a,c) or BA.5 (b,d) bivalent booster vaccination at baseline, and 7 days, 28 days, and 3 months post-boost. Colors indicate the specific prime-boost regimen (red = Ad26.COV2.S prime, mRNA-1273.214 or mRNA-1273.222 boost; yellow = Ad26.COV2.S prime, BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-based prime, mRNA-1273.214 or mRNA-1273.222 boost; blue = mRNA-based prime, BNT162b2 Omicron BA.1 or BA.5 boost). Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers above the plots represent the respective geometric mean (titer) per timepoint. The line graphs next to each panel depict a time course of the respective geometric mean values with 95% confidence intervals.



Supplementary Figure S3. Antibody and T-cell responses after Omicron BA.5 bivalent booster vaccination separated by booster manufacturer. a-f, Detection of (ancestral) spike (S)-specific binding IgG antibodies (a,d), ancestral SARS-CoV-2 neutralizing antibodies (b,e), and T-cell responses measured by interferon-gamma (IFN-γ) release assay (IGRA) (c,f) after Omicron BA.1 (a-c) or BA.5 (d-f) bivalent booster vaccination with either mRNA-1273.214 or mRNA-1273.222 (orange) or BNT162b2 Omicron BA.1 or BA.5 (teal) at baseline, and 7 days, 28 days, and 3 months post-boost. Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers above the plots represent the respective geometric mean (titer) per timepoint.



Supplementary Figure S4. Correlations between ancestral SARS-CoV-2 and variant-specific neutralizing antibodies. a,b, Correlations between neutralizing antibodies against ancestral SARS-CoV-2 and the Omicron BA.1, BA.5, and XBB.1.5 variants after Omicron BA.1 (**a**) or BA.5 (**b**) bivalent vaccination at 3 months post-boost. Colors indicate the specific prime-boost regimen (red = Ad26.COV2.S prime, mRNA-1273.214 or mRNA-1273.222 boost; yellow = Ad26.COV2.S prime, BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-based prime, mRNA-1273.214 or mRNA-1273.222 boost; blue = mRNA-based prime, BNT162b2 Omicron BA.1 or BA.5 boost). Correlations were evaluated by Spearman's r.



Supplementary Figure S5. Overview of post-vaccination breakthrough infections during the SWITCH-ON trial. a-c, Sampling procedure (left), and detection of S-specific IgG antibodies (middle) and T-cell responses measured by IGRA (right) for participants who had a breakthrough infection after Omicron BA.1 or BA.5 bivalent booster vaccination (study visit 1, SV1). Samples were either collected analogous to the pre-vaccination breakthrough infection group depicted in **Figure 5** at 7 and 28 days after testing positive (**a**), or outside of this regimen as a pre- and post-infection sample (**b,c**). Infections were either confirmed by positive test result (**a,b**), or via detection of nucleocapsid-specific antibodies (N-ELISA) (**c**).

Supplementary Table S1. List of investigators from the SWITCH-ON research group.

First name(s)	Surname	Organization
Anna	van de Hoef	Erasmus MC
Isabelle	Veerman Roders	Erasmus MC
Nathalie	Tjon	Erasmus MC
Karenin	van Grafhorst	Erasmus MC
Nella	Nieuwkoop	Erasmus MC
Faye	de Wilt	Erasmus MC
Sandra	Scherbeijn	Erasmus MC
Babs E.	Verstrepen	Erasmus MC
Marion	Ferren	Erasmus MC
Kim	Handrejk	Erasmus MC
Katharina S.	Schmitz	Erasmus MC
Koen	Wijnans	Erasmus MC
Aldert C.P.	Lamoré	Erasmus MC
Jenny	Schnyder	Amsterdam UMC
Olga	Starozhitskaya	Amsterdam UMC
Agnes	Harskamp	Amsterdam UMC
Irma	Maurer	Amsterdam UMC
Brigitte	Boeser-Nunnink	Amsterdam UMC
Marga	MangasRuiz	Amsterdam UMC
Renate	Akkerman	UMCG
Martin	Beukema	UMCG

Jacqueline J.	deVries-Idema	UMCG
Sander	Nijhof	UMCG
Frederique	Visscher	UMCG
Jopie	Zuidema	UMCG
Vivian W.M.	Slagter	LUMC
Kitty	Suijk-Benschop	LUMC
Jos	Fehrmann-Naumann	LUMC
Annelies	van Wengen-Stevenhagen	LUMC
Eva	Spaargaren	LUMC
Naomi	Olthof	LUMC
Anouk J.E.	de Vreede	LUMC
Jytte	Blokland	LUMC

Supplementary Table S2. Baseline characteristics of trial participants in direct boost group.						
		Total	Ad26.COV2.S prime/BNT162b2 Omicron BA.1 boost	mRNA-based prime/BNT162b2 Omicron BA.1 boost	Ad26.COV2.S prime/mRNA- 1273.214	mRNA-based prime/mRNA-1273.214
		n = 193	n = 41	n = 45	n = 48	n = 59
	Female	148 (77%)	30 (73%)	35 (78%)	31 (65%)	52 (88%)
	Male	45 (23%)	11 (27%)	10 (22%)	17 (35%)	7 (12%)
	Age	47.0 (36.0- 53.0)	36.0 (28.0-41.0)	35.0 (28.0-40.0)	52.5 (50.0- 55.0)	53.0 (50.0- 57.0)
	ВМІ	24.4 (22.6- 27.4)	23.9 (22.6-25.8)	23.7 (21.5-26.3)	25.2 (23.0- 27.6)	25.0 (23.1- 27.7)
Ancestry	African	2 (1%)	0 (0%)	1 (2%)	1 (2%)	0 (0%)
	Asian	6 (3%)	0 (0%)	3 (7%)	0 (0%)	3 (5%)
	European	179 (93%)	39 (95%)	40 (89%)	47 (98%)	53 (90%)
	North-american	1 (1%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)

	South-american	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Other	5 (3%)	2 (5%)	0 (0%)	0 (0%)	3 (5%)
Occupation in hospital	Administrative/policy maker	29 (15%)	7 (17%)	3 (7%)	11 (23%)	8 (14%)
	Medical doctor	15 (8%)	2 (5%)	4 (9%)	0 (0%)	9 (15%)
	Facility services	3 (2%)	1 (2%)	1 (2%)	1 (2%)	0 (0%)
	Management	24 (12%)	4 (10%)	3 (7%)	9 (19%)	8 (14%)
	Supportive staff clinic/emergency department	2 (1%)	1 (2%)	0 (0%)	0 (0%)	1 (2%)
	Supportive staff outpatient clinic	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (3%)
	Researcher	43 (22%)	14 (34%)	15 (33%)	6 (13%)	8 (14%)
	Nurse	11 (6%)	0 (0%)	4 (9%)	0 (0%)	7 (12%)
	Other	64 (33%)	12 (29%)	15 (33%)	21 (44%)	16 (27%)
Comorbidities	Cardiovascular diseases	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (3%)

	Pulmonary diseases	9 (5%)	0 (0%)	2 (4%)	2 (4%)	5 (8%)
	Diabetes mellitus	3 (2%)	0 (0%)	1 (2%)	2 (4%)	0 (0%)
	Liver diseases	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (3%)
	Kidney diseases	3 (2%)	1 (2%)	1 (2%)	0 (0%)	1 (2%)
N-ELISA on study visit 1	Negative	158 (82%)	33 (80%)	40 (89%)	44 (92%)	41 (69%)
(vaccination day)	Positive	35 (18%)	8 (20%)	5 (11%)	4 (8%)	18 (31%)
N-ELISA on study visit 4 (± 3	Negative	150 (78%)	30 (73%)	36 (80%)	42 (88%)	42 (71%)
months post- vaccination)	Positive	38 (20%)	11 (27%)	7 (16%)	4 (8%)	16 (27%)
Original center	Amsterdam University Medical Center	21 (11%)	5 (12%)	8 (18%)	3 (6%)	5 (8%)
	Erasmus Medical Center, Rotterdam	134 (69%)	23 (56%)	35 (78%)	24 (50%)	52 (88%)
	Leiden University Medical Center	15 (8%)	7 (17%)	0 (0%)	8 (17%)	0 (0%)

	University Medical Center Groningen	23 (12%)	6 (15%)	2 (4%)	13 (27%)	2 (3%)
Median time	Between study 1 and 2	7.0 (7.0-7.0)	7.0 (7.0-7.0)	7.0 (7.0-7.0)	7.0 (7.0-7.0)	7.0 (7.0-7.0)
	Between study 1 and 3	28.0 (28.0- 28.0)	28.0 (28.0-28.0)	28.0 (28.0-28.0)	28.0 (28.0- 28.0)	28.0 (28.0- 28.0)
	Between study 1 and 4	77.0 (77.0- 77.0)	77.0 (77.0-77.0)	77.0 (77.0-77.0)	77.0 (77.0- 77.0)	77.0 (77.0- 77.0)
	Between last booster and bivalent booster	298.0 (266.0- 310.0)	267.0 (259.0- 306.0)	303.0 (297.0- 310.0)	266.0 (262.3- 287.0)	307.0 (303.0- 310.0)

Note: categorical variables are presented as numbers (percentages), continuous variables are presented as median (interquartile range).

Note: the N-ELISA on study visit 4 was not performed for all participants as some did not attend this study visit. Numbers and percentages thus may slightly deviate from the total group size.

		Total	Ad26.COV2.S prime/BNT162b2 Omicron BA.5 boost	mRNA-based prime/BNT162b2 Omicron BA.5 boost	Ad26.COV2.S prime/mRNA- 1273.222 boost	mRNA-based prime/mRNA- 1273.222 boost
		n = 157	n = 37	n = 43	n = 41	n = 36
	Female	112 (71%)	24 (65%)	32 (74%)	30 (73%)	26 (72%)
	Male	45 (29%)	13 (35%)	11 (26%)	11 (27%)	10 (28%)
	Age	46.0 (37.0- 53.0)	47.0 (38.0-54.0)	48.0 (37.0-52.0)	46.0 (36.0- 54.0)	45.0 (37.0- 52.0)
	ВМІ	24.6 (22.1- 27.5)	24.7 (22.1-26.9)	24.1 (22.2-27.7)	24.5 (22.0- 25.8)	25.5 (21.9- 29.2)
Ancestry	African	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Asian	4 (3%)	0 (0%)	1 (2%)	1 (2%)	2 (6%)
	European	143 (91%)	36 (97%)	39 (91%)	37 (90%)	31 (86%)
	North-american	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

	South-american	3 (2%)	0 (0%)	1 (2%)	1 (2%)	1 (3%)
	Other	7 (4%)	1 (3%)	2 (5%)	2 (5%)	2 (6%)
Occupation in	Administrative/policy maker	18 (11%)	5 (14%)	3 (7%)	6 (15%)	4 (11%)
	Medical doctor	14 (9%)	1 (3%)	7 (16%)	0 (0%)	6 (17%)
	Facility services	3 (2%)	1 (3%)	0 (0%)	2 (5%)	0 (0%)
	Management	12 (8%)	2 (5%)	1 (2%)	7 (17%)	2 (6%)
	Supportive staff clinic/emergency department	3 (2%)	0 (0%)	2 (5%)	0 (0%)	1 (3%)
	Supportive staff outpatient clinic	1 (1%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)
	Researcher	29 (18%)	10 (27%)	5 (12%)	9 (22%)	5 (14%)
	Nurse	13 (8%)	1 (3%)	8 (19%)	0 (0%)	4 (11%)
	Other	64 (41%)	17 (46%)	16 (37%)	17 (41%)	14 (39%)
Comorbidities	Cardiovascular diseases	4 (3%)	0 (0%)	1 (2%)	1 (2%)	2 (6%)

	Pulmonary diseases	7 (4%)	4 (11%)	1 (2%)	0 (0%)	2 (6%)
	Diabetes mellitus	1 (1%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)
	Liver diseases	2 (1%)	0 (0%)	0 (0%)	1 (2%)	1 (3%)
	Kidney diseases	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
N-ELISA on study visit 1	Negative	124 (79%)	30 (81%)	32 (74%)	33 (80%)	29 (81%)
(vaccination day)	Positive	32 (20%)	7 (19%)	10 (23%)	8 (20%)	7 (19%)
N-ELISA on study visit 4 (± 3	Negative	125 (80%)	29 (78%)	36 (84%)	31 (76%)	29 (81%)
months post- vaccination)	Positive	28 (18%)	8 (22%)	5 (12%)	8 (20%)	7 (19%)
Original center	Amsterdam University Medical Center	20 (13%)	5 (14%)	6 (14%)	6 (15%)	3 (8%)
	Erasmus Medical Center, Rotterdam	107 (68%)	21 (57%)	36 (84%)	19 (46%)	31 (86%)
	Leiden University Medical Center	13 (8%)	6 (16%)	0 (0%)	7 (17%)	0 (0%)

	University Medical Center Groningen	17 (11%)	5 (14%0	1 (2%)	9 (22%)	2 (6%)
Median time	Between study 1 and 2	7.0 (7.0-7.0)	7.0 (7.0-7.0)	7.0 (7.0-7.0)	7.0 (7.0-7.0)	7.0 (7.0-7.0)
	Between study 1 and 3	28.0 (28.0- 28.0)	28.0 (28.0-28.0)	28.0 (28.0-28.0)	28.0 (28.0- 28.0)	28.0 (28.0- 28.0)
	Between study 1 and 4	98.0 (98.0- 98.0)	98.0 (98.0-98.0)	98.0 (98.0-98.0)	98.0 (98.0- 98.0)	98.0 (98.0- 98.0)
	Between last booster and bivalent booster	368.0 (336.0- 483.0)	336.0 (329.0- 364.0)	378.0 (365.5- 381.0)	337.0 (335.0- 372.0)	377.0 (372.3- 381.0)

Note: categorical variables are presented as numbers (percentages), continuous variables are presented as median (interquartile range).

Note: one participant refused to disclose the their weight, therefore their BMI was excluded.

Note: the N-ELISA on study visit 4 was not performed for all participants as some did not attend this study visit. Numbers and percentages thus may slightly deviate from the total group size.

Supplementary Table S4. Data availability for both groups

	Direct boost group (n=193)	Postponed boost group (n=157)
	Available data (%)	Available data (%)
Liaison - Study visit 1	193 (100%)	156 (99%)
Liaison - Study visit 2	191 (99%)	151 (96%)
Liaison - Study visit 3	182 (94%)	142 (90%)
Liaison - Study visit 4	168 (87%)	132 (84%)
Nucleocapsid - Study visit 1	193 (100%)	156 (99%)
Nucleocapsid - Study visit 4	188 (97%)	153 (97%)
IGRA Ag2 - Study visit 1	189 (98%)	155 (99%)
IGRA Ag2 - Study visit 2	190 (98%)	146 (93%)
IGRA Ag2 - Study visit 3	181 (94%)	142 (90%)
IGRA Ag2 - Study visit 4	164 (85%)	113 (72%)
PRNT50 ancestral - Study visit 1	54 (28%)	46 (29%)
PRNT50 ancestral - Study visit 2	56 (29%)	45 (29%)
PRNT50 ancestral - Study visit 3	54 (28%)	42 (27%)
PRNT50 ancestral - Study visit 4	51 (26%)	37 (24%)
PRNT50 BA.1 - Study visit 1	52 (27%)	46 (29%)
PRNT50 BA.1 - Study visit 2	53 (27%)	43 (27%)
PRNT50 BA.1 - Study visit 3	53 (27%)	40 (25%)

PRNT50 BA.1 - Study visit 4	50 (26%)	37 (24%)
PRNT50 BA.5 - Study visit 1	51 (26%)	46 (29%)
PRNT50 BA.5 - Study visit 2	51 (26%)	42 (27%)
PRNT50 BA.5 - Study visit 3	48 (25%)	39 (25%)
PRNT50 BA.5 - Study visit 4	46 (24%)	37 (24%)
PRNT50 XBB.1.5 - Study visit 1	0 (0%)	0 (0%)
PRNT50 XBB.1.5 - Study visit 2	0 (0%)	0 (0%)
PRNT50 XBB.1.5 - Study visit 3	0 (0%)	0 (0%)
PRNT50 XBB.1.5 - Study visit 4	48 (25%)	37 (24%)